Information Provided By:
Fly News Breaks for August 24, 2016
CLVS
Aug 24, 2016 | 09:18 EDT
Janney Capital analyst Roy Buchanan raised his fair value estimate for Clovis to $30 from $21 after the company announced that the New Drug Application filing for its rucaparib for the treatment of BRCA-mutant ovarian cancer has been accepted, with efficacy data look roughly in line with the analyst's expectations. Buchanan thinks the drug will get approved by or before the February 23, 2017 PDUFA date. He reiterates a Buy rating on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.